257 related articles for article (PubMed ID: 31394007)
21. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
Cohen JA; Imrey PB; Planchon SM; Bermel RA; Fisher E; Fox RJ; Bar-Or A; Sharp SL; Skaramagas TT; Jagodnik P; Karafa M; Morrison S; Reese Koc J; Gerson SL; Lazarus HM
Mult Scler; 2018 Apr; 24(4):501-511. PubMed ID: 28381130
[TBL] [Abstract][Full Text] [Related]
22. Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series.
Nicholas RS; Rhone EE; Mariottini A; Silber E; Malik O; Singh-Curry V; Turner B; Scalfari A; Ciccarelli O; Sormani MP; Olavarria E; Mehra V; Gabriel I; Kazmi MA; Muraro P;
Neurology; 2021 Aug; 97(9):e890-e901. PubMed ID: 34253634
[TBL] [Abstract][Full Text] [Related]
23. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
[TBL] [Abstract][Full Text] [Related]
24. Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation.
Tolf A; Fagius J; Carlson K; Åkerfeldt T; Granberg T; Larsson EM; Burman J
Acta Neurol Scand; 2019 Nov; 140(5):320-327. PubMed ID: 31297793
[TBL] [Abstract][Full Text] [Related]
25. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
[TBL] [Abstract][Full Text] [Related]
26. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.
Mancardi GL; Sormani MP; Di Gioia M; Vuolo L; Gualandi F; Amato MP; Capello E; Currò D; Uccelli A; Bertolotto A; Gasperini C; Lugaresi A; Merelli E; Meucci G; Motti L; Tola MR; Scarpini E; Repice AM; Massacesi L; Saccardi R;
Mult Scler; 2012 Jun; 18(6):835-42. PubMed ID: 22127896
[TBL] [Abstract][Full Text] [Related]
27. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
Krishnan C; Kaplin AI; Brodsky RA; Drachman DB; Jones RJ; Pham DL; Richert ND; Pardo CA; Yousem DM; Hammond E; Quigg M; Trecker C; McArthur JC; Nath A; Greenberg BM; Calabresi PA; Kerr DA
Arch Neurol; 2008 Aug; 65(8):1044-51. PubMed ID: 18541787
[TBL] [Abstract][Full Text] [Related]
28. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation.
Fagius J; Lundgren J; Oberg G
Mult Scler; 2009 Feb; 15(2):229-37. PubMed ID: 18805841
[TBL] [Abstract][Full Text] [Related]
29. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
30. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
[TBL] [Abstract][Full Text] [Related]
31. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients.
Carreras E; Saiz A; Marín P; Martínez C; Rovira M; Villamor N; Aymerich M; Lozano M; Fernández-Avilés F; Urbano-Izpizua A; Montserrat E; Graus F
Haematologica; 2003 Mar; 88(3):306-14. PubMed ID: 12651270
[TBL] [Abstract][Full Text] [Related]
32. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
[TBL] [Abstract][Full Text] [Related]
33. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus.
Burt RK; Traynor A; Statkute L; Barr WG; Rosa R; Schroeder J; Verda L; Krosnjar N; Quigley K; Yaung K; Villa Bs M; Takahashi M; Jovanovic B; Oyama Y
JAMA; 2006 Feb; 295(5):527-35. PubMed ID: 16449618
[TBL] [Abstract][Full Text] [Related]
34. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
[TBL] [Abstract][Full Text] [Related]
35. Long-term follow-up more than 10 years after HSCT: a monocentric experience.
Frau J; Carai M; Coghe G; Fenu G; Lorefice L; La Nasa G; Mamusa E; Vacca A; Marrosu MG; Cocco E
J Neurol; 2018 Feb; 265(2):410-416. PubMed ID: 29270686
[TBL] [Abstract][Full Text] [Related]
36. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Sormani MP; Muraro PA; Saccardi R; Mancardi G
Mult Scler; 2017 Feb; 23(2):201-204. PubMed ID: 27207454
[TBL] [Abstract][Full Text] [Related]
37. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS.
Saiz A; Carreras E; Berenguer J; Yagüe J; Martínez C; Marín P; Rovira M; Pujol T; Arbizu T; Graus F
Neurology; 2001 Apr; 56(8):1084-9. PubMed ID: 11320183
[TBL] [Abstract][Full Text] [Related]
38. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party.
Henes J; Oliveira MC; Labopin M; Badoglio M; Scherer HU; Del Papa N; Daikeler T; Schmalzing M; Schroers R; Martin T; Pugnet G; Simoes B; Michonneau D; Marijt EWA; Lioure B; Olivier Bay J; Snowden JA; Rovira M; Huynh A; Onida F; Kanz L; Marjanovic Z; Farge D
Haematologica; 2021 Feb; 106(2):375-383. PubMed ID: 31949011
[TBL] [Abstract][Full Text] [Related]
39. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
40. Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America.
Burt RK; Tappenden P; Han X; Quigley K; Arnautovic I; Sharrack B; Snowden JA; Hartung D
Mult Scler Relat Disord; 2020 Oct; 45():102404. PubMed ID: 32731201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]